CELTIC-19 / Alaya.bio - LARVOL DELTA

Alaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy Platform (Businesswire) - "Alaya.bio...announces today the acquisition of all assets previously owned by Ixaka France...Alaya.bio intends to leverage its combined assets to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered....This acquisition accelerates Alaya.bio's programs significantly, providing data showing preclinical proof of concept of the anti-tumoral efficacy of in vivo engineered CAR T cells in immunocompetent mouse models. It includes a broad and robust patent portfolio, preclinical data, and exclusive licenses for polymeric nanoparticle technology."

M&A • Preclinical • Hematological Malignancies • Oncology

CELTIC-19 Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency (Businesswire) - "Ixaka Ltd...announces that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product."

European regulatory • Hematological Malignancies • Oncology